Virios Therapeutics: The ‘Virus Hypothesis’ That Stands to Change the Lives of 10M Americans


Company’s September Phase 2b trial results could be transformative for fibromyalgia patients

New York, New York–(Newsfile Corp. – August 8, 2022) – PCG Digital — Life may change for the better for the 10 million Americans suffering from fibromyalgia. The development-stage biotech Virios Therapeutics, Inc. (NASDAQ: VIRI) is anticipating the reporting of phase 2b treatment results for its lead fibromyalgia treatment candidate this September and continues to add value through its research and development of compelling clinical assets for multiple categories of viruses.

To view the source version of this press release, please visit